TISSUE Regenix has said the development of its regenerative medical technology is looking "promising" following clinical tests.
The business, based at York Science Park, has announced “promising” results from an on-going clinical test of its dCELL Vascular Patch, which is intended to surgically repair peripheral arteries to remove blockages and improve blood flow.
Antony Odell, managing director of the business, said: “These mid-stage results look very promising. The preliminary data show that after a year, the dCELL Vascular Patch demonstrates similar behaviour to patients’ own veins, with no significant adverse effects”
The tests, which are being carried out on 21 patients, aged between 47 and 78, for another year, also showed it had a lower frequency of infection and took less time to stop bleeding post procedure compared to other synthetic products.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here